Dr.laura Deming
Pharmaceutical Sciences
Alexo Therapeutics
Ireland
Biography
A Forbes 30 under 30 star and partner at The Longevity Fund, Ms. Deming has wanted to cure aging since the age of 8. After years working on nematode longevity at UCSF, Ms. Deming matriculated at MIT at 14 to work on artificial organogenesis and bone aging. At 17, she was one of the youngest 20 under 20 fellows awarded $100,000 by Peter Thiel to pursue her venture full time. Ms. Deming is currently a full-time partner at The Longevity Fund, an early stage venture capital fund backing companies which target the aging process to treat disease, with investments in gene editing, small molecule therapeutics, and novel methods to treat disease. A Forbes 30 under 30 star and partner at The Longevity Fund, Ms. Deming has wanted to cure aging since the age of 8. After years working on nematode longevity at UCSF, Ms. Deming matriculated at MIT at 14 to work on artificial organogenesis and bone aging. At 17, she was one of the youngest 20 under 20 fellows awarded $100,000 by Peter Thiel to pursue her venture full time. Ms. Deming is currently a full-time partner at The Longevity Fund, an early stage venture capital fund backing companies which target the aging process to treat disease, with investments in gene editing, small molecule therapeutics, and novel methods to treat disease.
Research Interest
structural biology of adaptive immunity
